|Thyroid-like follicular renal cell carcinoma|
Thyroid-like follicular renal cell carcinoma is rare subtype of renal cell carcinoma.
Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.
Carcinoma is a category of types of cancer that develop from epithelial cells. Specifically, a carcinoma is a cancer that begins in a tissue that lines the inner or outer surfaces of the body, and that arises from cells originating in the endodermal, mesodermal or ectodermal germ layer during embryogenesis.
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney.
Papillary (collecting) ducts are anatomical structures of the kidneys, previously known as the ducts of Bellini. Papillary ducts represent the most distal portion of the collecting duct. They receive renal filtrate from several medullary collecting ducts and empty into a minor calyx. Papillary ducts continue the work of water reabsorption and electrolyte balance initiated in the collecting tubules.
An oncocytoma is a tumor made up of oncocytes, epithelial cells characterized by an excessive amount of mitochondria, resulting in an abundant acidophilic, granular cytoplasm. The cells and the tumor that they compose are often benign but sometimes may be premalignant or malignant.
A chromophobe is a histological structure that does not stain readily, and thus appears relatively pale under the microscope.
Axitinib is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
Collecting duct carcinoma (CDC), is a type of kidney cancer that originates in the papillary duct of the kidney. It is rare, accounting for 1-3% of all kidney cancers. It is also recently described; a 2002 review found just 40 case reports worldwide. Previously, due to its location, CDC was commonly diagnosed as renal cell carcinoma or a subtype of renal cell carcinoma. However, CDC does not respond well to chemotherapy drugs used for renal cell carcinoma, and progresses and spreads more quickly.
A renal oncocytoma is a tumour of the kidney made up of oncocytes, a special kind of cell.
Renal medullary carcinoma is a rare type of cancer that affects the kidney. It tends to be aggressive, difficult to treat, and is often metastatic at the time of diagnosis. Most individuals with this type of cancer have sickle cell trait or rarely sickle cell disease, suggesting that the sickle cell trait may be a risk factor for this type of cancer.
Kidney tumours are tumours, or growths, on or in the kidney. These growths can be benign or malignant.
Tivozanib is an oral VEGF receptor tyrosine kinase inhibitor. It has completed a Phase 3 investigation for the treatment of first line patients with renal cell carcinoma. The results from this first line study did not lead to US FDA approval, but tivozanib was approved by the European Medicines Agency (EMA) in August 2017.
Girentuximab is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.
Clear cell papillary renal cell carcinoma (CCPRCC) is a rare subtype of renal cell carcinoma (RCC) that has microscopic morphologic features of papillary renal cell carcinoma and clear cell renal cell carcinoma, yet is pathologically distinct based on molecular changes and immunohistochemistry.
The Clear Cell Renal Cell Carcinoma (CCRCC) is a type of renal cell carcinoma.
Papillary renal cell carcinomas are subtypes of renal cell carcinoma (RCC).
Tubulocystic renal cell carcinoma is rare subtype of renal cell carcinoma.
Acquired cystic kidney disease-associated renal cell carcinoma is rare subtype of renal cell carcinoma. It is most commonly seen in people with end-stage kidney disease who have a much higher risk of developing acquired cystic kidney disease (ACKD). Affected individuals have small kidneys with several cysts and their risk of renal cell carcinoma is 30 times higher than people without ACKD.
This is a timeline of kidney cancer, describing especially major discoveries and advances in treatment of the disease.
|This medical sign article is a stub. You can help Wikipedia by expanding it.|